Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/BioNTech’s second bivalent COVID-19 booster approved by MHRA

The adapted vaccine targets the original virus and Omicron BA.4 and BA.5 strains

Pfizer

Pfizer/BioNTech’s jointly developed bivalent COVID-19 vaccine has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and is designed to target both the original strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 strains.

In each dose of the booster vaccine, 50% of the vaccine targets the original virus strain and the other 50% specifically targets Omicron (BA.4-5).

The updated booster is the second bivalent vaccine produced by Pfizer/BioNTech to be granted MHRA approval, having successfully met the regulator’s criteria for safety, quality and effectiveness.

The vaccine has already been approved for use as a booster dose in those aged 12 years and above, following a review of evidence by the Commission on Human Medicines, which advises ministers on the safety, efficacy and quality of medicinal products.

The approval is supported by evidence provided on the original Pfizer/BioNTech COVID-19 vaccine and its adapted vaccines, including extensive safety and effectiveness data for the original vaccine, clinical data from the bivalent original/omicron BA.1 vaccine and safety data from an on-going clinical trial.

The data demonstrated that the most common side effects recorded with the new bivalent vaccine were the same as results seen for other versions of the vaccine. It was reported that side-effects were typically mild and self-resolving, and no new safety concerns were found.

All approved COVID-19 booster vaccines help to improve the protection obtained from earlier doses of the vaccine and help give longer-term protection against getting seriously ill from COVID-19. For the UK autumn booster campaign, the MHRA advises people to come forward for their booster vaccination when invited to do so.

The MHRA’s approval of the updated bivalent COVID-19 booster vaccine follows on from Pfizer/BioNTech’s most recent update, in which the companies provided a clinical data update for their Omicron BA.4/BA.5-adapted bivalent vaccine for use in adults.

The updated results, announced on 4 November, from the phase 2/3 clinical trial demonstrated a substantially higher immune response in adults, compared to the original vaccine.

It has been suggested in a recent publication in The Lancet that COVID-19 vaccines have prevented up to 20 million deaths in the first year of use.

Article by
Fleur Jeffries

10th November 2022

From: Research, Regulatory

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...